6473 related articles for article (PubMed ID: 3664532)
21. HLA-DR antigen expression in primary melanomas of the skin.
Bröcker EB; Suter L; Sorg C
J Invest Dermatol; 1984 Mar; 82(3):244-7. PubMed ID: 6366074
[TBL] [Abstract][Full Text] [Related]
22. Differential expression of HLA-DR, DQ, and DP antigens in primary and metastatic melanoma.
van Vreeswijk H; Ruiter DJ; Bröcker EB; Welvaart K; Ferrone S
J Invest Dermatol; 1988 May; 90(5):755-60. PubMed ID: 3283252
[TBL] [Abstract][Full Text] [Related]
23. Melanocytic nevi in histologic association with primary cutaneous melanoma of superficial spreading and nodular types: effect of tumor thickness.
Sagebiel RW
J Invest Dermatol; 1993 Mar; 100(3):322S-325S. PubMed ID: 8440914
[TBL] [Abstract][Full Text] [Related]
24. In situ analysis of antigens on malignant and benign cells of the melanocyte lineage. Differential expression of two surface molecules, gp75 and p89.
Holzmann B; Johnson JP; Kaudewitz P; Riethmüller G
J Exp Med; 1985 Feb; 161(2):366-77. PubMed ID: 3973533
[TBL] [Abstract][Full Text] [Related]
25. Use of monoclonal antibodies in detection of melanoma-associated antigens in intact human tumors.
Thompson JJ; Herlyn MF; Elder DE; Clark WH; Steplewski Z; Koprowski H
Am J Pathol; 1982 Jun; 107(3):357-61. PubMed ID: 6177248
[TBL] [Abstract][Full Text] [Related]
26. The number and localization of CD68+ and CD163+ macrophages in different stages of cutaneous melanoma.
Salmi S; Siiskonen H; Sironen R; Tyynelä-Korhonen K; Hirschovits-Gerz B; Valkonen M; Auvinen P; Pasonen-Seppänen S
Melanoma Res; 2019 Jun; 29(3):237-247. PubMed ID: 30399061
[TBL] [Abstract][Full Text] [Related]
27. Progression-related expression of beta3 integrin in melanomas and nevi.
Van Belle PA; Elenitsas R; Satyamoorthy K; Wolfe JT; Guerry D; Schuchter L; Van Belle TJ; Albelda S; Tahin P; Herlyn M; Elder DE
Hum Pathol; 1999 May; 30(5):562-7. PubMed ID: 10333228
[TBL] [Abstract][Full Text] [Related]
28. [Monoclonal antibodies in pigmented lesions].
Puig L; Moreno A; Moragas JM
Med Cutan Ibero Lat Am; 1987; 15(6):481-8. PubMed ID: 3323707
[TBL] [Abstract][Full Text] [Related]
29. In situ analysis of the mononuclear cell infiltrate in primary malignant melanoma of the skin.
Poppema S; Bröcker EB; de Leij L; Terbrack D; Visscher T; Ter Haar A; Macher E; Thé TH; Sorg C
Clin Exp Immunol; 1983 Jan; 51(1):77-82. PubMed ID: 6219841
[TBL] [Abstract][Full Text] [Related]
30. Human monoclonal antibodies that distinguish cutaneous malignant melanomas from benign nevi in fixed tissue sections.
Imam A; Mitchell MS; Modlin RL; Taylor CR; Kempf RA; Kan-Mitchell J
J Invest Dermatol; 1986 Feb; 86(2):145-8. PubMed ID: 3528308
[TBL] [Abstract][Full Text] [Related]
31. Expression of NM23 protein in acquired melanocytic nevi, malignant melanoma and metastases of malignant melanoma: an immunohistological assessment in human skin.
Reichrath J; Seyfried P; Braun R; Müller SM; Baum HP; Bahmer FA
Dermatology; 1997; 194(2):136-9. PubMed ID: 9094461
[TBL] [Abstract][Full Text] [Related]
32. Antigenic profiles of individual-matched pairs of primary and melanoma metastases.
Meije CB; Swart GW; Lepoole C; Das PK; Van den Oord JJ
Hum Pathol; 2009 Oct; 40(10):1399-407. PubMed ID: 19386352
[TBL] [Abstract][Full Text] [Related]
33. In situ expression of transforming growth factor beta is associated with melanoma progression and correlates with Ki67, HLA-DR and beta 3 integrin expression.
Moretti S; Pinzi C; Berti E; Spallanzani A; Chiarugi A; Boddi V; Reali UM; Giannotti B
Melanoma Res; 1997 Aug; 7(4):313-21. PubMed ID: 9293481
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic utility of combining PRAME and HMB-45 stains in primary melanocytic tumors.
Rasic D; Korsgaard N; Marcussen N; Precht Jensen EM
Ann Diagn Pathol; 2023 Dec; 67():152211. PubMed ID: 37717457
[TBL] [Abstract][Full Text] [Related]
35. Immunoreactivity with the anti-MAGE antibody 57B in malignant melanoma: frequency of expression and correlation with prognostic parameters.
Busam KJ; Iversen K; Berwick M; Spagnoli GC; Old LJ; Jungbluth AA
Mod Pathol; 2000 Apr; 13(4):459-65. PubMed ID: 10786815
[TBL] [Abstract][Full Text] [Related]
36. The differential reactivity of benign and malignant nevomelanocytic lesions with mouse monoclonal antibody TNKH1.
Nakanishi T; Hashimoto K
Cancer; 1987 Apr; 59(7):1340-4. PubMed ID: 3545436
[TBL] [Abstract][Full Text] [Related]
37. Expression of the neuroglandular antigen and analogues in melanoma. CD9 expression appears inversely related to metastatic potential of melanoma.
Si Z; Hersey P
Int J Cancer; 1993 Apr; 54(1):37-43. PubMed ID: 8478146
[TBL] [Abstract][Full Text] [Related]
38. Incidence of new and changed nevi and melanomas detected using baseline images and dermoscopy in patients at high risk for melanoma.
Banky JP; Kelly JW; English DR; Yeatman JM; Dowling JP
Arch Dermatol; 2005 Aug; 141(8):998-1006. PubMed ID: 16103329
[TBL] [Abstract][Full Text] [Related]
39. Cytoplasmic BRMS1 expression in malignant melanoma is associated with increased disease-free survival.
Slipicevic A; Holm R; Emilsen E; Ree Rosnes AK; Welch DR; Mælandsmo GM; Flørenes VA
BMC Cancer; 2012 Feb; 12():73. PubMed ID: 22356677
[TBL] [Abstract][Full Text] [Related]
40. Expression of melan-A (MART1) in benign melanocytic nevi and primary cutaneous malignant melanoma.
Busam KJ; Chen YT; Old LJ; Stockert E; Iversen K; Coplan KA; Rosai J; Barnhill RL; Jungbluth AA
Am J Surg Pathol; 1998 Aug; 22(8):976-82. PubMed ID: 9706977
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
